Recent Pfizer Press Releases
- Results Reflect the Animal Health Business (Zoetis(1)) as a Discontinued Operation for Second-Quarter and Year-to-Date 2013 and 2012
- Second-Quarter 2013 Revenues of $13.0 Billion, Adjusted Diluted EPS(2) of $0.56 and Reported Diluted EPS(3) of $1.98
- Repurchased $3.3 Billion and $8.7 Billion of Common Stock in Second-Quarter and to Date in 2013, Respectively
- Accepted 405.1 Million Shares of Common Stock in Exchange for Remaining Zoetis(1) Interest
- Reaffirmed All Components of Adjusted Financial Guidance
- Announced Plan to Create Separate, Internal, Global Innovative and Value Businesses
Pfizer Plans to Work with the European Medicines Agency (EMA) to Resubmit Marketing Authorization Application (MAA)
Pfizer Inc. (NYSE: PFE) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has confirmed its April 25, 2013, opinion to recommend against approval of XELJANZ® (tofacitinib citrate)
more...
Statements Include First Quarter of 2013 and First and Second Quarters of 2012
For the information of investors, Pfizer Inc. (NYSE:PFE) is providing the unaudited condensed consolidated statements of income (statements of income) of Pfizer for the three months ended March 31, 2013, July 1, 2012 and April 1, 2012, with the financial results of its Animal Health business
more...
Pfizer and Generations United challenge people and communities to define how they want to Get Old
more...
Pfizer and Generations United challenge people and communities to define how they want to Get Old
more...
Pfizer and Generations United challenge people and communities to define how they want to Get Old
more...
Pfizer and Generations United challenge people and communities to define how they want to Get Old
|
WHAT:
|
On July 11, 2013 Pfizer and Generations United will release results of an inter-generational survey of Atlanta respondents attitudes towards aging. The “2013 Get Old Survey” reveals that Atlanta-area residents of all ages are concerned about their ability to get old the way they want, and feel their communities are not prepared to support an aging population.
|
Phase 3 AMPLIFY Results Published in New England Journal of Medicine and Presented as a Late-Breaker at the Congress of the International Society on Thrombosis and Haemostasis Show:
· Eliquis Was Noninferior to Current Standard of Care for Treatment of Both Symptomatic Deep Vein Thrombosis and Pulmonary Embolism Conditions
· 69 Percent Relative Risk Reduction for Major Bleeding in Patients on Eliquis Compared to Current Standard of Care
PRINCETON, NJ and NEW YORK, June 30 – Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced the results of the six month Phase 3 AMPLIFY trial of 5,395 patients with acute venous thromboembolism (VTE), which includes symptomatic deep vein thrombosis (DVT) and/or pulmonary embolism (PE).
more...
Board of Directors Authorizes New $10 Billion Share Repurchase Program
NEW YORK, N.Y., June 27 – The board of directors of Pfizer Inc. today declared a 24-cent third-quarter 2013 dividend on the company’s common stock, payable September 4, 2013, to shareholders of record at the close of business on August 2, 2013. The third-quarter 2013 cash dividend will be the 299th consecutive quarterly dividend paid by Pfizer.
NEW YORK, N.Y. June 27 – Pfizer Inc. (NYSE: PFE) today announced the final results of its offer to its shareholders to exchange all, some or none of their shares of Pfizer common stock for shares of Zoetis Inc. (NYSE: ZTS) common stock owned by Pfizer.
The Advil® Relief in Action Program Continues its Commitment to Supporting Volunteers Who Don’t Let Pain Hold Them Back From Helping Others, in Support of Wounded Warrior Project®, by Partnering with Tough Mudder® at Events Across the Country
Madison, N.J., June 26 — Pfizer Inc. (NYSE: PFE) announces today that Advil® is the Official Pain Reliever of Tough Mudder® as part of the Advil® Relief in Action campaign that celebrates volunteers who don’t let pain get in the way of providing relief to others.
NEW YORK, N.Y., June 25 -- Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, July 30, 2013. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter 2013 Performance Report, to be issued that morning.
Pfizer Inc. (NYSE: PFE) today announced that, based on preliminary results, its previously announced offer to its shareholders to exchange all, some or none of their shares of Pfizer common stock for shares of Zoetis Inc.
more...
NEW YORK, N.Y., June 21 - Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Application (sNDA)for the XELJANZ® (tofacitinib citrate) rheumatoid arthritis (RA) indication seeking expansion of the label to include inhibition of progression of structural damage. The FDA will review the sNDA and is expected to provide a decision by February 2014, based on the anticipated Prescription Drug User Fee Act (PDUFA) action date for the sNDA.